Context for Progyny’s Recent Stock Move

Progyny (PGNY) has recently attracted investor attention after a period where the stock rose about 35% over the past month and roughly 41% over the past 3 months, prompting closer scrutiny of its fundamentals.

The company operates a fertility, family building, and women’s health benefits platform in the US, with its stock now trading around US$25.11 and a market value of about US$2.1b.

That sharp 35% 1 month share price return and 41% 3 month share price return comes after a weaker year to date share price return and a mixed longer term picture, with a 1 year total shareholder return of 14.24% but declines over the 3 and 5 year periods. This suggests that recent momentum contrasts with earlier caution.

If Progyny’s rebound has you thinking about where else renewed momentum might be taking hold in healthcare technology, this is a useful moment to scan 39 healthcare AI stocks.

With Progyny’s shares rebounding sharply and trading around US$25.11 despite weaker multi year returns, the key question is whether the stock still trades below its underlying worth or if the market already prices in future growth.

Most Popular Narrative: 18.8% Undervalued

Progyny’s most followed narrative puts fair value at about $30.91 per share, which sits above the recent $25.11 close and frames the recent rebound as only part of the story.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Want to see what kind of revenue mix and margin profile that sort of expansion is built on? The narrative lays out a clear growth path that is tied to steady earnings compounding and a future earnings multiple that assumes Progyny keeps earning its place among faster growing healthcare platforms.

Result: Fair Value of $30.91 (UNDERVALUED)

However, you still need to factor in that tighter employer benefit budgets and rising competition in fertility benefits could put pressure on Progyny’s revenue growth and margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle On Valuation

The first narrative leans on fair value around $30.91, which suggests upside from the current $25.11 share price. On simple P/E maths though, Progyny trades at 29.1x, slightly above its 28.1x fair ratio and the US Healthcare sector at 23.2x. This points to less room for error. So is this a mispricing or just a premium story?

Next Steps

That mix of optimism and caution only matters if you evaluate it against your own expectations, so take a closer look at the company’s 3 key rewards.

Looking for more investment ideas?

If Progyny has sharpened your focus, do not stop here. Use this momentum to line up a watchlist of fresh opportunities tailored to your goals.

• Target resilient balance sheets and steady fundamentals by scanning the solid balance sheet and fundamentals stocks screener (47 results) that filters for financial strength.
• Hunt for quality at attractive prices with the 46 high quality undervalued stocks that focuses on strong businesses trading below their assessed worth.
• Spot lesser known opportunities before others do by checking the screener containing 22 high quality undiscovered gems built around companies with solid fundamentals that fly under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.